[go: up one dir, main page]

MX2019004845A - Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico. - Google Patents

Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.

Info

Publication number
MX2019004845A
MX2019004845A MX2019004845A MX2019004845A MX2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A
Authority
MX
Mexico
Prior art keywords
proteasome inhibitors
methods
cylodextrin
peptide proteasome
complexation
Prior art date
Application number
MX2019004845A
Other languages
English (en)
Inventor
Sean Dalziel
Evan Lewis
Peter Shwonek
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019004845(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of MX2019004845A publication Critical patent/MX2019004845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida. Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración.
MX2019004845A 2012-05-08 2014-11-07 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico. MX2019004845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
US201361777475P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
MX2019004845A true MX2019004845A (es) 2021-03-31

Family

ID=48326170

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013552A MX364393B (es) 2012-05-08 2013-05-08 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
MX2019004845A MX2019004845A (es) 2012-05-08 2014-11-07 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014013552A MX364393B (es) 2012-05-08 2013-05-08 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.

Country Status (25)

Country Link
US (1) US10159746B2 (es)
EP (2) EP2662094B1 (es)
JP (1) JP6410264B2 (es)
KR (5) KR20220088949A (es)
CN (2) CN107693772A (es)
AU (2) AU2013259573B2 (es)
CA (1) CA2873044C (es)
CL (1) CL2014003055A1 (es)
DK (1) DK2662094T3 (es)
EA (1) EA033614B1 (es)
ES (1) ES2981576T3 (es)
FI (1) FI2662094T3 (es)
HK (2) HK1207827A1 (es)
HR (1) HRP20240724T1 (es)
HU (1) HUE066956T2 (es)
IL (1) IL235553B (es)
LT (1) LT2662094T (es)
MX (2) MX364393B (es)
PL (1) PL2662094T3 (es)
PT (1) PT2662094T (es)
RS (1) RS65647B1 (es)
SG (2) SG10201609318UA (es)
SI (1) SI2662094T1 (es)
SM (1) SMT202400264T1 (es)
WO (1) WO2013169897A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE066956T2 (hu) 2012-05-08 2024-09-28 Onyx Therapeutics Inc Peptid proteaszóma inhibitorok formulázására alkalmas ciklodextrin komplexálási eljárások
EP3021862B1 (en) 2013-07-19 2017-08-30 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
DK3478670T3 (da) 2016-06-29 2023-05-15 Kezar Life Sciences Krystallinske salte af peptidepoxyketon-immunproteasomhæmmer
JP7065044B2 (ja) 2016-06-29 2022-05-11 ケザール ライフ サイエンシズ ペプチドエポキシケトン免疫プロテアソーム阻害剤、およびその前駆体の調製プロセス
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
IL266964B2 (en) * 2016-11-29 2024-06-01 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
JP7204670B2 (ja) * 2017-05-03 2023-01-16 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン及びブスルファンを含有する組成物
TW202114697A (zh) 2019-07-01 2021-04-16 瑞士商歐庫利斯公司 用於穩定包括藥物的水性組成物之pH值的方法
CN110882221B (zh) * 2019-11-29 2021-06-29 健进制药有限公司 一种注射用卡非佐米冻干制剂的生产工艺
EP4134068A4 (en) * 2020-04-09 2024-02-07 Bika Biotechnology (Guangzhou) Co., Ltd. Bendamustine composition and use thereof
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870060A (en) 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
ATE323110T1 (de) 1997-07-01 2006-04-15 Pfizer Prod Inc Verfahren zur herstellung von einem cyclodextrin
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
JP2004510826A (ja) 2000-10-12 2004-04-08 ヴィローミクス　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング ウイルス感染の治療剤
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
JP2007517069A (ja) * 2003-12-31 2007-06-28 サイデックス・インコーポレイテッド スルホアルキルエーテルγ−シクロデキストリンおよびコルチコステロイドを含む吸入製剤
CA2562411A1 (en) * 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
ES2408216T3 (es) * 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
CA2626122A1 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions comprising lipoxygenase inhibitors and cyclodextrin
MX2010003732A (es) * 2007-10-04 2010-08-09 Onyx Therapeutics Inc Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido.
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
PE20120059A1 (es) * 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
CN102946879B (zh) 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
KR20160033795A (ko) 2012-02-28 2016-03-28 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
BR112012028726B1 (pt) 2012-05-08 2021-07-13 Onyx Therapeutics, Inc. Método para preparar uma composição farmacêutica com baixo teor de cloreto
HUE066956T2 (hu) 2012-05-08 2024-09-28 Onyx Therapeutics Inc Peptid proteaszóma inhibitorok formulázására alkalmas ciklodextrin komplexálási eljárások
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
EP4410374A2 (en) 2024-08-07
HUE066956T2 (hu) 2024-09-28
CA2873044C (en) 2021-01-26
KR20190137963A (ko) 2019-12-11
PL2662094T3 (pl) 2024-08-05
AU2018200444A1 (en) 2018-02-08
SG10201609318UA (en) 2016-12-29
HK1207827A1 (en) 2016-02-12
KR20150008165A (ko) 2015-01-21
KR20220088949A (ko) 2022-06-28
AU2013259573B2 (en) 2018-02-15
LT2662094T (lt) 2024-07-10
WO2013169897A1 (en) 2013-11-14
CA2873044A1 (en) 2013-11-14
RS65647B1 (sr) 2024-07-31
SI2662094T1 (sl) 2024-09-30
KR102054329B1 (ko) 2019-12-10
JP2015516430A (ja) 2015-06-11
IL235553A0 (en) 2015-01-29
DK2662094T3 (da) 2024-07-08
CL2014003055A1 (es) 2015-02-13
PT2662094T (pt) 2024-07-04
IL235553B (en) 2018-04-30
CN107693772A (zh) 2018-02-16
ES2981576T3 (es) 2024-10-09
EA033614B1 (ru) 2019-11-11
EA201491994A1 (ru) 2015-04-30
SMT202400264T1 (it) 2024-07-09
US20150111838A1 (en) 2015-04-23
JP6410264B2 (ja) 2018-10-24
CN104411334A (zh) 2015-03-11
KR20240119191A (ko) 2024-08-06
FI2662094T3 (fi) 2024-06-26
HK1250927A1 (zh) 2019-01-18
EP4410374A3 (en) 2024-11-06
EP2662094B1 (en) 2024-04-17
HRP20240724T1 (hr) 2024-08-30
EP2662094A1 (en) 2013-11-13
AU2018200444B2 (en) 2019-10-31
MX2014013552A (es) 2015-05-08
MX364393B (es) 2019-04-24
KR20200130748A (ko) 2020-11-19
AU2013259573A1 (en) 2014-11-27
SG11201407337QA (en) 2014-12-30
US10159746B2 (en) 2018-12-25

Similar Documents

Publication Publication Date Title
MX2019004845A (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
MY196510A (en) Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
CY1124690T1 (el) Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη
UA105229C2 (uk) Фармацевтичний склад
AU2012214029A8 (en) Rorgammat inhibitors
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
TN2015000324A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2013009527A3 (en) Factor ixa inhibitors
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
UA109281C2 (uk) Фармацевтична композиція, яка містить похідне аміду або його фармацевтично прийнятну сіль
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
NZ708821A (en) Lfa-1 inhibitor formulations
MX343540B (es) Compuesto de tiazol y metodo de preparacion y uso del mismo.
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
MX2015007309A (es) Derivado de hidantoina.
TN2014000060A1 (en) Benzothiazolone compound
MX2010003112A (es) Formas de dosificacion solubles que contienen derivados de cephem adecuados para administracion parenteral.
MX2010009513A (es) Composicion farmaceutica.
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MX2015017864A (es) Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
SA114350532B1 (ar) عملية لتخليق 3، 4-داي ميثوكسي باي سيكلو [4، 2، 0] أوكتا-1، 3، 5- ترايين-7-كربو نيتريل، والاستخدام في تخليق إيفابرادين وأملاح إضافة منه باستخدام حمض مقبول صيدلانياً